search
Back to results

The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection (CurHP)

Primary Purpose

Positivity for Helicobacter Pylori

Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Curcumin
Sponsored by
Gingold Belfer Rachel
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Positivity for Helicobacter Pylori

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • positivity for Helicobacter pylori by urease test and gastric biopsy

Exclusion Criteria:

  • prior treatment for H. pylori
  • allergy to penicillin
  • gastric outlet obstruction
  • pregnancy or breast feeding
  • inability to understand the informed consent

Sites / Locations

  • Rabin Medical Center
  • Rabin Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Triple therapy, helicobacter pylori

triple therapy+curcumin helicobacter pylori

Arm Description

Curcumin will be added to the regular triple therapy

Outcomes

Primary Outcome Measures

Urea breath test

Secondary Outcome Measures

Full Information

First Posted
December 17, 2013
Last Updated
December 13, 2014
Sponsor
Gingold Belfer Rachel
search

1. Study Identification

Unique Protocol Identification Number
NCT02018328
Brief Title
The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection
Acronym
CurHP
Official Title
The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection
Study Type
Interventional

2. Study Status

Record Verification Date
December 2014
Overall Recruitment Status
Unknown status
Study Start Date
January 2014 (undefined)
Primary Completion Date
December 2015 (Anticipated)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Gingold Belfer Rachel

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Background and Aims H.pylori is a common human pathogen by which almost 50% of the world population is infected. According to the accepted guidelines, once H.pylori infection has been diagnosed,first line therapy with three drugs should be given. The triple treatment includes proton-pump-inhibitor-clarithromycin-amoxicillin but its eradication rate is only 70-80%. Curcumin has many beneficial merits and it was also been demonstrated to be efficient in inhibition of H.pylori infection, in vitro.Therefore we aim to investigate whether addition of Curcumin to the standard triple therapy will increase the eradication rate of H.pylori infection. Methods 150 consecutive patients that will undergo esophagogastroscopy in our Gastroenterology department and will be positive for H.pylori according to urease test and then by gastric biopsy, will be included. The patients will be randomized to two different treatments, according to binomial distribution. 75 patients will be treated with the standard triple therapy for 10 days and the other 75, will be treated for 10 days, with triple therapy combined with Curcumin that will be given three times a day. During the treatment the patients will complete an adverse effect's questionnaires. 6 weeks after the completion of the treatment the patients will undergo urea breath test to confirm eradication. Patients will be asked to avoid antibiotics, bismuth compounds or proton-pump-inhibitor until the second urea-breath-test. We will compare the eradication rate and the adverse effects between the two groups by using SPSS

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Positivity for Helicobacter Pylori

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Triple therapy, helicobacter pylori
Arm Type
No Intervention
Arm Title
triple therapy+curcumin helicobacter pylori
Arm Type
Experimental
Arm Description
Curcumin will be added to the regular triple therapy
Intervention Type
Dietary Supplement
Intervention Name(s)
Curcumin
Primary Outcome Measure Information:
Title
Urea breath test
Time Frame
6 weeks after the completion of the treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: positivity for Helicobacter pylori by urease test and gastric biopsy Exclusion Criteria: prior treatment for H. pylori allergy to penicillin gastric outlet obstruction pregnancy or breast feeding inability to understand the informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rachel Gingold belfer, MD
Email
RahelGB@clalit.org.il
Facility Information:
Facility Name
Rabin Medical Center
City
Petah Tikva
ZIP/Postal Code
49100
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rachel Gingold Belfer, MD
Phone
974-54-2405895
Email
RahelGB@clalit.org.il
First Name & Middle Initial & Last Name & Degree
Rachel Gingold Belfer, MD
Facility Name
Rabin Medical Center
City
Petah tikva
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rachel Gingold Belfer, MD
Phone
974-54-2405895
Email
RahelGB@clalit.org.il
First Name & Middle Initial & Last Name & Degree
Rachel Ginold Belfer, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
15044093
Citation
Foryst-Ludwig A, Neumann M, Schneider-Brachert W, Naumann M. Curcumin blocks NF-kappaB and the motogenic response in Helicobacter pylori-infected epithelial cells. Biochem Biophys Res Commun. 2004 Apr 16;316(4):1065-72. doi: 10.1016/j.bbrc.2004.02.158.
Results Reference
background

Learn more about this trial

The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection

We'll reach out to this number within 24 hrs